Corrigendum to: Interpreting the new FDA draft potency guidance: an RNA cell therapy perspective
Cell & Gene Therapy Insights 2024; 10(11), 1623
DOI: 10.18609/cgti.2024.187
Published: 19 December
Corrigendum
This corrigendum contains corrections the following article: Interpreting the new FDA draft potency guidance: an RNA cell therapy perspective. Cell & Gene Therapy Insights 2024; 10(10), 1433–1442. DOI: 10.18609/cgti.2024.164. The details of the amendment are below and the corrected article can be accessed here.
In the version of this article initially published, the title was Interpreting the new FDA draft potency guidance: an mRNA gene modified cell therapy perspective. However, the title should be Interpreting the new FDA draft potency guidance: an RNA cell therapy perspective (as displayed above). This error has been corrected in the HTML and PDF versions of this article as of December 18, 2024.